Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Executive Summary

Company plans to meet with caregivers and consider other options before moving forward.


Related Content

Best Defense Is Good Offense: PhRMA Wants PBMs To 'Share The Savings'
Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug
Shaping A Shkreli Bill: Voucher Abuse Solution May Stumble On FDA Effects
Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Exonics Using CRISPR To Develop One-Time Treatment for Duchenne
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Cost Versus Value: Earnings Calls Spotlight US Pricing Reforms
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts